Tag: J&J

Stereotaxis and Johnson & Johnson’s Biosense Webster Extend Development Alliance and Supply Agreement

ST. LOUIS, June 25, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with Johnson & Johnson’s Biosense Webster, Inc. The amendment […]

Biosense Webster, Inc. Launches Study To Evaluate Novel High Power, Short Duration Modality For Treatment Of Atrial Fibrillation

IRVINE, Calif., May 2, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its QDOT AF Study.** The study will evaluate the delivery of high power, short duration ablation […]